Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN- in patients with progressive metastatic renal cell carcinoma
The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-dose interleukin-2 (LD-IL-2), granulocyte-monocyte colony-stimulating factor (GM-CSF) and interferon-alpha 2b (IFNalpha) in progressive metastatic renal cell carcinoma. I...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2003-05, Vol.88 (9), p.1346-1351 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1351 |
---|---|
container_issue | 9 |
container_start_page | 1346 |
container_title | British journal of cancer |
container_volume | 88 |
creator | Verra, N Jansen, R Groenewegen, G Mallo, H Kersten, M J Bex, A Vyth-Dreese, F A Sein, J van de Kasteele, W Nooijen, W J de Waal, M Horenblas, S de Gast, G C |
description | The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-dose interleukin-2 (LD-IL-2), granulocyte-monocyte colony-stimulating factor (GM-CSF) and interferon-alpha 2b (IFNalpha) in progressive metastatic renal cell carcinoma. In a multicentre phase II study, 59 evaluable patients received two to six cycles of subcutaneous IL-2 (4 mIU m(-2)), GM-CSF (2.5 microg kg(-1)) and IFNalpha (5 mIU flat(-1)) for 12 days per 3 weeks with evaluation after every two cycles. Cycles were repeated in responding or stable patients. Data were analysed after a median of 30 months follow-up (range 16-48 months). In 42 patients, the immunologic response was studied and related to response and survival. The main toxicity were flu-like symptoms, malaise and transient liver enzyme elevations, necessitating IL-2 reduction to 2 mIU m(-2) in 29 patients, which should be considered the maximal tolerable dose. The response was 24% (eight out of 34, three complete response (CR), five partial response (PR)) in patients with metachronic metastases and 12% (three out of 25, 2CR, 1PR) in patients with synchronic metastases. Overall response was 19% (11 out of 59). Median survival was 9.5 months. All tested patients showed expansion and/or activation of lymphocytes, T cells and subsets, NK cells, eosinophils and monocytes. Pretreatment HLA-DR levels on monocytes and number of CD4(+)HLA-DR(+) cells correlated with response. Pretreatment number of CD4(+)HLA-DR(+) cells and postimmunotherapy levels of lymphocytes, CD3(+), CD4(+) and CD8(+) T cells, but not of NK or B cells, correlated with prolonged survival. Immunotherapy with concurrent subcutaneous GM-CSF, LD-IL-2 and IFNalpha has limited toxicity, can be given as outpatient treatment and can induce durable CR. Response and survival with this form of immunotherapy seem to be more dependent on expansion/activation of T cells than of NK cells. |
doi_str_mv | 10.1038/sj.bjc.6600915 |
format | Article |
fullrecord | <record><control><sourceid>proquest_natur</sourceid><recordid>TN_cdi_proquest_journals_230005360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>984957411</sourcerecordid><originalsourceid>FETCH-LOGICAL-n490-7c9cf07c1e869b803d555965d4bfe17a6da4f764063c826f4b51129ab5ee08d23</originalsourceid><addsrcrecordid>eNotkF9LwzAUxYMoOKevvgnBZzOTtEmbRxluDqY-uPeSpqlraZOaP459AT-3ge3lXi7n3B-HA8A9wQuCs_LZ94u6VwvOMRaEXYAZYRlFpKTFJZhhjAuEBcXX4Mb7Pp0Cl8UM_G3GMRob9trJ6QgPXdhDZY2KzmkToI-1ikEabaOH63e0_Fo9wcEeUGO9hpstolCaBm5WHwh2Bk4ydOnNnziTs99Oe9_9ajjqIH1IsoIJLAeo9JCGdKozdpS34KqVg9d35z0Hu9XrbvmGtp_rzfJli0wuMCqUUC0uFNElF3WJs4YxJjhr8rrVpJC8kXlb8BzzTJWUt3nNCKFC1kxrXDY0m4PHEzZF-4nah6q30aU4vqJZ6oRlHCfTw8lkZIhOV5PrRumO1bnY7B_smG2k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230005360</pqid></control><display><type>article</type><title>Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN- in patients with progressive metastatic renal cell carcinoma</title><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Verra, N ; Jansen, R ; Groenewegen, G ; Mallo, H ; Kersten, M J ; Bex, A ; Vyth-Dreese, F A ; Sein, J ; van de Kasteele, W ; Nooijen, W J ; de Waal, M ; Horenblas, S ; de Gast, G C</creator><creatorcontrib>Verra, N ; Jansen, R ; Groenewegen, G ; Mallo, H ; Kersten, M J ; Bex, A ; Vyth-Dreese, F A ; Sein, J ; van de Kasteele, W ; Nooijen, W J ; de Waal, M ; Horenblas, S ; de Gast, G C</creatorcontrib><description>The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-dose interleukin-2 (LD-IL-2), granulocyte-monocyte colony-stimulating factor (GM-CSF) and interferon-alpha 2b (IFNalpha) in progressive metastatic renal cell carcinoma. In a multicentre phase II study, 59 evaluable patients received two to six cycles of subcutaneous IL-2 (4 mIU m(-2)), GM-CSF (2.5 microg kg(-1)) and IFNalpha (5 mIU flat(-1)) for 12 days per 3 weeks with evaluation after every two cycles. Cycles were repeated in responding or stable patients. Data were analysed after a median of 30 months follow-up (range 16-48 months). In 42 patients, the immunologic response was studied and related to response and survival. The main toxicity were flu-like symptoms, malaise and transient liver enzyme elevations, necessitating IL-2 reduction to 2 mIU m(-2) in 29 patients, which should be considered the maximal tolerable dose. The response was 24% (eight out of 34, three complete response (CR), five partial response (PR)) in patients with metachronic metastases and 12% (three out of 25, 2CR, 1PR) in patients with synchronic metastases. Overall response was 19% (11 out of 59). Median survival was 9.5 months. All tested patients showed expansion and/or activation of lymphocytes, T cells and subsets, NK cells, eosinophils and monocytes. Pretreatment HLA-DR levels on monocytes and number of CD4(+)HLA-DR(+) cells correlated with response. Pretreatment number of CD4(+)HLA-DR(+) cells and postimmunotherapy levels of lymphocytes, CD3(+), CD4(+) and CD8(+) T cells, but not of NK or B cells, correlated with prolonged survival. Immunotherapy with concurrent subcutaneous GM-CSF, LD-IL-2 and IFNalpha has limited toxicity, can be given as outpatient treatment and can induce durable CR. Response and survival with this form of immunotherapy seem to be more dependent on expansion/activation of T cells than of NK cells.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6600915</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group</publisher><ispartof>British journal of cancer, 2003-05, Vol.88 (9), p.1346-1351</ispartof><rights>Copyright Nature Publishing Group May 6, 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2725,27923,27924</link.rule.ids></links><search><creatorcontrib>Verra, N</creatorcontrib><creatorcontrib>Jansen, R</creatorcontrib><creatorcontrib>Groenewegen, G</creatorcontrib><creatorcontrib>Mallo, H</creatorcontrib><creatorcontrib>Kersten, M J</creatorcontrib><creatorcontrib>Bex, A</creatorcontrib><creatorcontrib>Vyth-Dreese, F A</creatorcontrib><creatorcontrib>Sein, J</creatorcontrib><creatorcontrib>van de Kasteele, W</creatorcontrib><creatorcontrib>Nooijen, W J</creatorcontrib><creatorcontrib>de Waal, M</creatorcontrib><creatorcontrib>Horenblas, S</creatorcontrib><creatorcontrib>de Gast, G C</creatorcontrib><title>Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN- in patients with progressive metastatic renal cell carcinoma</title><title>British journal of cancer</title><description>The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-dose interleukin-2 (LD-IL-2), granulocyte-monocyte colony-stimulating factor (GM-CSF) and interferon-alpha 2b (IFNalpha) in progressive metastatic renal cell carcinoma. In a multicentre phase II study, 59 evaluable patients received two to six cycles of subcutaneous IL-2 (4 mIU m(-2)), GM-CSF (2.5 microg kg(-1)) and IFNalpha (5 mIU flat(-1)) for 12 days per 3 weeks with evaluation after every two cycles. Cycles were repeated in responding or stable patients. Data were analysed after a median of 30 months follow-up (range 16-48 months). In 42 patients, the immunologic response was studied and related to response and survival. The main toxicity were flu-like symptoms, malaise and transient liver enzyme elevations, necessitating IL-2 reduction to 2 mIU m(-2) in 29 patients, which should be considered the maximal tolerable dose. The response was 24% (eight out of 34, three complete response (CR), five partial response (PR)) in patients with metachronic metastases and 12% (three out of 25, 2CR, 1PR) in patients with synchronic metastases. Overall response was 19% (11 out of 59). Median survival was 9.5 months. All tested patients showed expansion and/or activation of lymphocytes, T cells and subsets, NK cells, eosinophils and monocytes. Pretreatment HLA-DR levels on monocytes and number of CD4(+)HLA-DR(+) cells correlated with response. Pretreatment number of CD4(+)HLA-DR(+) cells and postimmunotherapy levels of lymphocytes, CD3(+), CD4(+) and CD8(+) T cells, but not of NK or B cells, correlated with prolonged survival. Immunotherapy with concurrent subcutaneous GM-CSF, LD-IL-2 and IFNalpha has limited toxicity, can be given as outpatient treatment and can induce durable CR. Response and survival with this form of immunotherapy seem to be more dependent on expansion/activation of T cells than of NK cells.</description><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNotkF9LwzAUxYMoOKevvgnBZzOTtEmbRxluDqY-uPeSpqlraZOaP459AT-3ge3lXi7n3B-HA8A9wQuCs_LZ94u6VwvOMRaEXYAZYRlFpKTFJZhhjAuEBcXX4Mb7Pp0Cl8UM_G3GMRob9trJ6QgPXdhDZY2KzmkToI-1ikEabaOH63e0_Fo9wcEeUGO9hpstolCaBm5WHwh2Bk4ydOnNnziTs99Oe9_9ajjqIH1IsoIJLAeo9JCGdKozdpS34KqVg9d35z0Hu9XrbvmGtp_rzfJli0wuMCqUUC0uFNElF3WJs4YxJjhr8rrVpJC8kXlb8BzzTJWUt3nNCKFC1kxrXDY0m4PHEzZF-4nah6q30aU4vqJZ6oRlHCfTw8lkZIhOV5PrRumO1bnY7B_smG2k</recordid><startdate>20030506</startdate><enddate>20030506</enddate><creator>Verra, N</creator><creator>Jansen, R</creator><creator>Groenewegen, G</creator><creator>Mallo, H</creator><creator>Kersten, M J</creator><creator>Bex, A</creator><creator>Vyth-Dreese, F A</creator><creator>Sein, J</creator><creator>van de Kasteele, W</creator><creator>Nooijen, W J</creator><creator>de Waal, M</creator><creator>Horenblas, S</creator><creator>de Gast, G C</creator><general>Nature Publishing Group</general><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20030506</creationdate><title>Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN- in patients with progressive metastatic renal cell carcinoma</title><author>Verra, N ; Jansen, R ; Groenewegen, G ; Mallo, H ; Kersten, M J ; Bex, A ; Vyth-Dreese, F A ; Sein, J ; van de Kasteele, W ; Nooijen, W J ; de Waal, M ; Horenblas, S ; de Gast, G C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-n490-7c9cf07c1e869b803d555965d4bfe17a6da4f764063c826f4b51129ab5ee08d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verra, N</creatorcontrib><creatorcontrib>Jansen, R</creatorcontrib><creatorcontrib>Groenewegen, G</creatorcontrib><creatorcontrib>Mallo, H</creatorcontrib><creatorcontrib>Kersten, M J</creatorcontrib><creatorcontrib>Bex, A</creatorcontrib><creatorcontrib>Vyth-Dreese, F A</creatorcontrib><creatorcontrib>Sein, J</creatorcontrib><creatorcontrib>van de Kasteele, W</creatorcontrib><creatorcontrib>Nooijen, W J</creatorcontrib><creatorcontrib>de Waal, M</creatorcontrib><creatorcontrib>Horenblas, S</creatorcontrib><creatorcontrib>de Gast, G C</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verra, N</au><au>Jansen, R</au><au>Groenewegen, G</au><au>Mallo, H</au><au>Kersten, M J</au><au>Bex, A</au><au>Vyth-Dreese, F A</au><au>Sein, J</au><au>van de Kasteele, W</au><au>Nooijen, W J</au><au>de Waal, M</au><au>Horenblas, S</au><au>de Gast, G C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN- in patients with progressive metastatic renal cell carcinoma</atitle><jtitle>British journal of cancer</jtitle><date>2003-05-06</date><risdate>2003</risdate><volume>88</volume><issue>9</issue><spage>1346</spage><epage>1351</epage><pages>1346-1351</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-dose interleukin-2 (LD-IL-2), granulocyte-monocyte colony-stimulating factor (GM-CSF) and interferon-alpha 2b (IFNalpha) in progressive metastatic renal cell carcinoma. In a multicentre phase II study, 59 evaluable patients received two to six cycles of subcutaneous IL-2 (4 mIU m(-2)), GM-CSF (2.5 microg kg(-1)) and IFNalpha (5 mIU flat(-1)) for 12 days per 3 weeks with evaluation after every two cycles. Cycles were repeated in responding or stable patients. Data were analysed after a median of 30 months follow-up (range 16-48 months). In 42 patients, the immunologic response was studied and related to response and survival. The main toxicity were flu-like symptoms, malaise and transient liver enzyme elevations, necessitating IL-2 reduction to 2 mIU m(-2) in 29 patients, which should be considered the maximal tolerable dose. The response was 24% (eight out of 34, three complete response (CR), five partial response (PR)) in patients with metachronic metastases and 12% (three out of 25, 2CR, 1PR) in patients with synchronic metastases. Overall response was 19% (11 out of 59). Median survival was 9.5 months. All tested patients showed expansion and/or activation of lymphocytes, T cells and subsets, NK cells, eosinophils and monocytes. Pretreatment HLA-DR levels on monocytes and number of CD4(+)HLA-DR(+) cells correlated with response. Pretreatment number of CD4(+)HLA-DR(+) cells and postimmunotherapy levels of lymphocytes, CD3(+), CD4(+) and CD8(+) T cells, but not of NK or B cells, correlated with prolonged survival. Immunotherapy with concurrent subcutaneous GM-CSF, LD-IL-2 and IFNalpha has limited toxicity, can be given as outpatient treatment and can induce durable CR. Response and survival with this form of immunotherapy seem to be more dependent on expansion/activation of T cells than of NK cells.</abstract><cop>London</cop><pub>Nature Publishing Group</pub><doi>10.1038/sj.bjc.6600915</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 2003-05, Vol.88 (9), p.1346-1351 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_proquest_journals_230005360 |
source | Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
title | Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN- in patients with progressive metastatic renal cell carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T20%3A12%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_natur&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20with%20concurrent%20subcutaneous%20GM-CSF,%20low-dose%20IL-2%20and%20IFN-%20in%20patients%20with%20progressive%20metastatic%20renal%20cell%20carcinoma&rft.jtitle=British%20journal%20of%20cancer&rft.au=Verra,%20N&rft.date=2003-05-06&rft.volume=88&rft.issue=9&rft.spage=1346&rft.epage=1351&rft.pages=1346-1351&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6600915&rft_dat=%3Cproquest_natur%3E984957411%3C/proquest_natur%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230005360&rft_id=info:pmid/&rfr_iscdi=true |